|

Daraxonrasib Clinical Trials

5 actively recruiting trials across 5 locations

Also known as: RMC-6236

Birmingham, Alabama1 trial

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Alabama Oncology

Phase 3

Duarte, California1 trial

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

City of Hope

Phase 1/2

Hartford, Connecticut1 trial

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Hartford Healthcare

Phase 3

Grand Rapids, Michigan1 trial

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

START Midwest

Phase 1

Fairfax, Virginia1 trial

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

NEXT Virginia

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.